TACT908

TACT908, also known as [2-(indolizin-1-yl)ethyl]dimethylamine (2ZEDMA), is a serotonin receptor agonist which is under development for the treatment of cluster headaches.^[1][2][3] It is an analogue and positional isomer of the tryptamine serotonergic psychedelic N,N-dimethyltryptamine (DMT) in which the indole ring has been replaced with an indolizine ring.^[1]

TACT908

Clinical data
Other names	TACT-908; Compound 28-12; 2ZEDMA; [2-(Indolizin-1-yl)ethyl]dimethylamine; Indolizine-DMT
Drug class	Serotonin receptor agonist; Serotonin 5-HT1B receptor agonist; Non-hallucinogenic serotonin 5-HT2A receptor agonist
Identifiers
IUPAC name 2-indolizin-1-yl-N,N-dimethylethanamine
PubChem CID	169203122
Chemical and physical data
Formula	C12H16N2
Molar mass	188.274 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN(C)CCC1=C2C=CC=CN2C=C1
InChI InChI=1S/C12H16N2/c1-13(2)9-6-11-7-10-14-8-4-3-5-12(11)14/h3-5,7-8,10H,6,9H2,1-2H3 Key:CBZZXMYTGARRHB-UHFFFAOYSA-N

The drug acts as a serotonin 5-HT_1B and 5-HT_2A receptor agonist.^[1][3] Its EC₅₀Tooltip half-maximal effective concentration at the serotonin 5-HT_2A receptor is 52 nM (E_maxTooltip maximal efficacy ≈ 30% of that of serotonin) and its EC₅₀ at the serotonin 5-HT_1B receptor is 143 nM.^[1] TACT908 is said to be a non-hallucinogenic serotonin 5-HT_2A receptor agonist.^[1][3] It showed little or no activity at 45 other screened targets, including the serotonin 5-HT_1A, 5-HT_2B, and 5-HT₃ receptors as well as the monoamine transporters (MATs).^[1] Other serotonin receptors besides the preceding, such as the serotonin 5-HT_2C receptor, were not assessed.^[1] The drug was a weak monoamine oxidase inhibitor (MAOI), specifically of monoamine oxidase A (MAO-A) (IC₅₀Tooltip half-maximal inhibitory concentration = 7,252 nM).^[1]

TACT908 is under development by Tactogen.^[1][2][3] It was patented by Matthew Baggott and Tactogen in 2023.^[1] As of January 2025, the drug is in preclinical research for cluster headaches.^[2][3]

The α-methyl and N-desmethyl analogue of TACT908, 1ZP2MA ([1-(indolizin-1-yl)propan-2-yl](methyl)amine or 1-(indolizin-1-yl)-N-methylpropan-2-amine), has also been characterized and described.^[1] It is the indolizine analogue of α,N-dimethyltryptamine (α,N-DMT or N-methyl-αMT).^[1] 1ZP2MA was found to be a potent dopamine releasing agent, with an EC₅₀ of 62 nM.^[1]

See also

• N,N-Dimethylisotryptamine (isoDMT)
• 1Z2MAP1O
• C-DMT
• TACT411
• TACT833
• List of investigational hallucinogens and entactogens

References

1. WO patent 2023183613A2, Matthew J. Baggott, "Indolizine compounds for the treatment of mental disorders or inflammation", published 2023 September 28, assigned to Tactogen
2. Haichin M (2024). "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 29 January 2025.
3. "Tactogen Inc – Pipeline". Tactogen Inc. Tactogen. 8 February 2021. Retrieved 29 January 2025. OUR PIPELINE: [...] COMPOUND: TACT908. TARGETS: 5-HT1B, 5-HT2A ***. INDICATION: Cluster Headache. Prevalence: 0.24%. STATUS: Preclinical. [...] ***Partial agonist at 2A, non-hallucinogenic.